A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Sanofi from a hold rating to a sell rating in a research report on Wednesday, August 3rd. TheStreet downgraded Sanofi from a buy rating to a hold rating in a research report on Monday, August 22nd. Berenberg Bank raised Sanofi from a hold rating to a buy rating in a research report on Thursday, September 8th. BNP Paribas raised Sanofi from an underperform rating to a neutral rating in a research report on Tuesday, September 13th. Finally, Piper Jaffray Cos. started coverage on Sanofi in a research report on Friday, September 23rd. They issued a neutral rating for the company. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. Sanofi presently has an average rating of Hold and a consensus target price of $60.50.
Shares of Sanofi (NYSE:SNY) opened at 38.67 on Monday. Sanofi has a 12 month low of $37.41 and a 12 month high of $51.88. The stock’s 50 day moving average price is $39.12 and its 200 day moving average price is $40.56. The firm has a market cap of $99.54 billion, a price-to-earnings ratio of 21.57 and a beta of 1.01.
Several large investors have recently modified their holdings of the company. Bessemer Group Inc. increased its stake in shares of Sanofi by 77.1% in the second quarter. Bessemer Group Inc. now owns 3,445 shares of the company’s stock valued at $144,000 after buying an additional 1,500 shares during the last quarter. Signaturefd LLC increased its stake in shares of Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock valued at $146,000 after buying an additional 490 shares during the last quarter. JFS Wealth Advisors LLC increased its stake in shares of Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock valued at $166,000 after buying an additional 134 shares during the last quarter. BlackRock Institutional Trust Company N.A. bought a new stake in shares of Sanofi during the first quarter valued at $175,000. Finally, Bradley Foster & Sargent Inc. CT bought a new stake in shares of Sanofi during the second quarter valued at $205,000. 9.42% of the stock is owned by institutional investors.
Sanofi Company Profile
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.